Menu Back to Master-Protocols-and-Complex-Innovative-Design


The evolution of clinical trial designs has accelerated since the onset of the pandemic to meet patient and logistical need. While elements of randomized control trials remain a gold standard, clinical trials continue to transform, building on innovations in study design and statistical approaches, as well as regulatory flexibilities, with the promise of bringing new medicines to patients more quickly than ever.

Supported by advancement in clinical trail operations, development of digital technologies along with strong partnerships and collaborations amongst key stakeholders, clinical trials are poised to reach more people and add efficiency to clinical drug development. Master protocol and complex innovative designs continue to provide frameworks that hold enormous promise for engaging patients more productively, increasing overall efficiency and improving successful outcomes.

DIA’s Master Protocols and Complex Innovative Design Meeting will bring together a truly multidisciplinary group of experts in clinical trial planning, execution, and analysis to share and discuss both the common and unique challenges and opportunities in the adoption of master protocols and complex innovative design. Join industry, patient, regulatory agency, other government, and NGO representatives to examine the growing body of knowledge, experience, and resources available to better meet patient needs through successful implementation of innovation in clinical trial designs.

Who should attend?

Professionals and students from industry, academia, and government involved in all phases of the healthcare product lifecycle who are interested in applying new skills and tools to improve program and project execution including:

  • Clinical Data Management
  • Clinical Data Management/eClinical
  • Clinical Research
  • Good Clinical Practice
  • Patient Engagement
  • Research & Development
  • Rare, Orphan Diseases
  • Strategic Planning
  • Statistics

Program Committee

  • Daniel  Millar, MBA
    Daniel Millar, MBA Senior Director, Strategic Business Transformation Quantitative Sciences
    Janssen Research & Development, United States
  • Robert A. Beckman, MD
    Robert A. Beckman, MD Professor of Oncology, Bioinformatics, and Biomathematics
    Georgetown University Medical Center, United States
  • Fanni  Natanegara, PhD
    Fanni Natanegara, PhD Research Advisor
    Eli Lilly and Company, United States
  • Zoran  Antonijevic, MSc
    Zoran Antonijevic, MSc Vice President, Statistical Consulting
    Abond CRO Inc., United States
  • Michelle  Detry, PhD
    Michelle Detry, PhD Director, Adaptive Trial Execution & Senior Statistical Scientist
    Berry Consultants LLC, United States
  • Kristin  Dolinski
    Kristin Dolinski Deputy Vice President, Science and Regulatory Advocacy
    PhRMA, United States
  • AnnCatherine M. Downing, PharmD
    AnnCatherine M. Downing, PharmD Senior Research Advisor - Clinical
    Eli Lilly and Company, United States
  • Anne-Marie  Duliege
    Anne-Marie Duliege Pancreatic Cancer Action Network
    Chief Medical Officer , United States
  • Yi  Liu, PhD
    Yi Liu, PhD Executive Director Biostatistics
    Nektar Therapeutics, United States
  • Cristiana  Mayer, DrSc, PhD
    Cristiana Mayer, DrSc, PhD Director, Statistics and Decision Sciences
    Janssen Research & Development, LLC, United States
  • Pritibha  Singh, MBA, MSc, PMP
    Pritibha Singh, MBA, MSc, PMP
    Novartis, Switzerland
  • Rui (Sammi)  Tang
    Rui (Sammi) Tang Vice President, Biometric of Oncology
    Servier Pharmaceuticals, United States
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions